KLOW Blend 80mg (with Bacteriostatic Water)

KLOW is a multi-peptide research preparation combining four well-characterized research peptides into a single lyophilized vial reconstituted with bacteriostatic water. The "KLOW" acronym is constructed from the component peptides: KPV (the lysine-proline-valine C-terminal tripeptide of α-melanocyte-stimulating hormone), Levocopper (a research-supply term for the copper-binding GHK-Cu peptide), BPC-157 (the body-protection-compound pentadecapeptide of gastric-juice origin), and TB-500 (the active fragment of Thymosin β4). Each component has its own substantial preclinical research literature in repair-related research models; the combined preparation is studied as a single research-context tool in models where multiple complementary repair-research mechanisms are of interest simultaneously.

This 80 mg combined-peptide research preparation provides the four components in a defined ratio suitable for combined-peptide research applications. The specific per-component mass and ratio appear on the supplier's certificate of analysis for each lot. The blend format is widely used in research-supply combination preparations because it provides a standardized multi-peptide exposure with a single reconstitution and single administration event.

This page is a research-only educational reference. The blend is supplied as a research-supply product for laboratory and research-supply use and is not intended for human consumption or any therapeutic application. No medical claims are made on this page.

KLOW is a four-peptide combination preparation. The individual components are:

KPV (Lysine-Proline-Valine). A tripeptide corresponding to the C-terminal three residues of α-melanocyte-stimulating hormone (α-MSH 11-13). Originally identified through structure-activity research on the anti-inflammatory activity of α-MSH, KPV retains substantial anti-inflammatory activity of the parent hormone while lacking the pigmentation-related melanocortin-receptor agonism. KPV has been studied in published research on intestinal inflammation, dermal inflammation, and immune-cell regulation.

GHK-Cu (Glycyl-Histidyl-Lysine, copper-bound). A tripeptide-copper complex originally identified by Loren Pickart in 1973 in human plasma as the active species responsible for hepatocyte-growth-stimulating activity. GHK-Cu has been studied extensively in research on wound healing, dermal extracellular-matrix synthesis, hair-follicle biology, and cosmetic-peptide applications. The copper coordination is structurally and functionally central to the molecule's activity.

BPC-157. A 15-amino-acid synthetic pentadecapeptide derived from a sequence within human gastric juice "body protection compound." BPC-157 has been studied for three decades in preclinical models of gastric and intestinal mucosal injury, tendon and ligament repair, vascular biology, and central-nervous-system protection, principally by the Sikiric laboratory in Zagreb and collaborators.

TB-500. A synthetic fragment of Thymosin β4 (the actin-binding 43-amino-acid peptide). The TB-500 fragment retains the actin-binding sequence motif of the parent thymosin and has been studied in published research on cardiac-tissue repair, wound-healing dynamics, and corneal-epithelium research.

The 80 mg combined preparation provides these four components in defined proportion as a lyophilized powder for reconstitution with bacteriostatic water. The combination preparation is intended for research applications where multiple complementary repair-research mechanisms are of interest, providing a single research-context tool rather than separate reconstitution and combination of four individual peptide preparations.

Each of the four KLOW components has its own characterization history in the published research literature spanning multiple decades:

GHK-Cu was characterized by Loren Pickart in 1973 through fractionation of human plasma activity that stimulated DNA synthesis in cultured hepatocytes. Pickart and subsequent investigators characterized the tripeptide structure, the copper-binding chemistry, and the broad effects on extracellular-matrix metabolism and cellular gene expression. GHK-Cu has remained a continuously active research compound through the subsequent five decades, with substantial application in wound-healing research and cosmetic-peptide development.

KPV emerged from structure-activity research on α-melanocyte-stimulating hormone in the 1990s-2000s, with the recognition that the C-terminal tripeptide retained anti-inflammatory activity of the parent hormone without the pigmentation-related melanocortin-receptor agonism. Subsequent published work characterized KPV effects on intestinal-inflammation models, dermal-inflammation models, and immune-cell biology.

BPC-157 was identified by Sikiric and colleagues at the University of Zagreb in the early 1990s through fractionation of human gastric juice extracts in models of gastric-mucosal injury. The pentadecapeptide fragment of the parent "body protection compound" has been studied in three decades of published preclinical literature in gastric, intestinal, tendon, ligament, vascular, and CNS-protection contexts.

TB-500 emerged from research on Thymosin β4, the actin-binding peptide characterized in thymic tissue in the 1980s and subsequently shown to have broad regulatory effects on actin dynamics and tissue repair. The TB-500 fragment was developed as a synthetically tractable research-supply form of the active thymosin sequence.

The combination of these four peptides into a single "KLOW" research preparation reflects a research-supply convention in which complementary repair-research peptides are combined into a single multi-peptide tool. The naming convention and specific ratio of components are research-supply naming and formulation choices; the underlying individual components are the well-characterized research compounds described above.

The four KLOW components engage different proposed repair-research mechanisms in the published literature, and the rationale for combination is that complementary mechanisms can be addressed simultaneously in research-context applications.

KPV mechanism. KPV is the C-terminal tripeptide of α-MSH and is studied for anti-inflammatory effects that appear largely independent of melanocortin-receptor agonism. Proposed mechanisms include direct effects on NF-κB signaling in epithelial and immune cells, effects on cytokine production by activated macrophages, and effects on neutrophil function. Published research on intestinal-inflammation models (DSS-colitis, TNBS-colitis), atopic-dermatitis models, and immune-cell culture has reported anti-inflammatory phenotypes with KPV treatment.

GHK-Cu mechanism. GHK-Cu is a copper-binding tripeptide that engages multiple proposed mechanisms in repair-research. The copper-coordination chemistry supports redox-active copper handling relevant to lysyl oxidase activity (collagen and elastin crosslinking) and to wound-healing oxidative biology. Published research has reported effects on gene expression of multiple extracellular-matrix components, including collagen synthesis, glycosaminoglycan synthesis, and metalloproteinase regulation. GHK-Cu effects on cellular gene expression have been characterized in microarray-scale gene-expression studies as broad and pleiotropic, reaching multiple pathways relevant to wound healing and tissue remodeling.

BPC-157 mechanism. The proposed BPC-157 mechanisms include effects on vascular and angiogenic biology (VEGF expression, granulation-tissue formation), modulation of the nitric-oxide system, effects on growth-factor receptor expression, and gastric and intestinal mucosal-protective effects. The specific molecular mechanism remains incompletely characterized after three decades of research, but the preclinical phenotypes in tissue-repair models are reasonably consistent across multiple research groups.

TB-500 mechanism. TB-500 retains the actin-binding sequence motif of Thymosin β4. The proposed mechanisms include direct effects on cellular actin dynamics (cytoskeletal remodeling supporting cell migration during wound healing), effects on inflammation, and pro-angiogenic effects. Cardiac-repair research, corneal-epithelium research, and dermal-wound research have characterized TB-500 effects in preclinical models.

In the combined KLOW research context, the four components offer: - Anti-inflammatory effects (KPV) - Extracellular-matrix and gene-expression effects (GHK-Cu) - Multi-axis tissue-repair signaling (BPC-157) - Actin-dynamics and cellular-migration effects (TB-500)

The combined-research-tool rationale is that complementary mechanisms can be engaged simultaneously, which may be relevant in tissue-repair research models that involve multiple parallel biological processes (inflammation, matrix synthesis, vascular development, cell migration, and so on). The combined preparation does not substitute for component-isolation research where mechanism attribution to a single component is the experimental goal; for such studies, individual single-peptide research preparations remain the appropriate tool.

The KLOW preparation is a lyophilized powder containing the four component peptides in defined proportion. Each component is independently synthesized:

KPV (Lys-Pro-Val) — tripeptide, molecular weight ~342 Da, produced by solid-phase peptide synthesis. The compact size supports straightforward synthesis and characterization.

GHK-Cu (Gly-His-Lys + Cu²⁺) — tripeptide-copper complex, molecular weight ~342 Da (peptide) + 63.5 Da (Cu) = ~405 Da (complex). The copper coordination is the structurally and functionally central feature.

BPC-157 — pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), molecular weight ~1,419 Da. Linear unmodified peptide produced by solid-phase synthesis.

TB-500 — synthetic fragment of Thymosin β4 (typical research-format sequence corresponds to residues 17-23 of the parent thymosin, "LKKTETQ", though specific TB-500 preparations may differ — refer to the supplier's certificate of analysis for the specific sequence). Molecular weight depends on the specific fragment; typically in the 800-900 Da range for the standard research-supply form.

The combined preparation is reconstituted with bacteriostatic water following standard lyophilized-peptide reconstitution practice. The combined-vial total mass is 80 mg as labeled; the per-component mass and the per-component reconstituted concentration appear on the supplier's certificate of analysis.

Storage of the lyophilized combined preparation follows standard research-supply practice: refrigerated or frozen for unreconstituted material, refrigerated for reconstituted solution within the relevant stability period. Refer to the supplier's documentation for specific storage and stability information.

Published research using the KLOW component peptides in combination or individually includes:

Cutaneous wound-healing research. Rodent and porcine dermal-wound models (excisional, incisional, burn, diabetic-wound) are studied with individual components (GHK-Cu, BPC-157, TB-500) and combinations. KPV adds an anti-inflammatory component that complements the matrix-synthesis and cellular-migration mechanisms of the other components.

Tendon and ligament repair research. Rodent tendinopathy and ligament-transection models have been studied with BPC-157 and TB-500 individually; combination research extends these models to multi-peptide preparations.

Gastrointestinal mucosal research. DSS-colitis, TNBS-colitis, and various gastric-injury models have been studied with KPV (anti-inflammatory effects) and BPC-157 (mucosal-protective effects); combination preparations provide a multi-mechanism research tool for these models.

Cosmetic and dermal-aging research. GHK-Cu is a central compound in cosmetic-peptide research; combinations with the other KLOW components extend this work to multi-mechanism research tools for dermal-aging and skin-repair applications.

Cardiac repair research. TB-500 has been studied in cardiac-tissue repair models; combination research can address overlapping anti-inflammatory and matrix-synthesis mechanisms relevant to cardiac-tissue remodeling.

Combination-pharmacology research. Studies addressing the interaction effects of multiple repair-research peptides in matched experimental conditions are well-served by a standardized multi-component preparation that eliminates the experimental variability of separate reconstitution and combination of individual peptides.

Mechanism-attribution research. The combined preparation is not the appropriate tool for studies whose goal is attribution of observed phenotypes to a specific single component; for that purpose, individual single-peptide research preparations are the appropriate tool. Combined preparations are appropriate where multi-component combination is the experimental variable of interest.

All applications are research-supply context: laboratory and research-supply use in cells, tissues, and rodent or other in-vivo models. The preparation is not for human consumption. Nothing on this page describes a clinical protocol or therapeutic use.

KLOW sits within a category of combined / multi-peptide research-supply preparations. The principal alternatives are the individual component research preparations and other combination preparations.

KLOW is a four-peptide combination research preparation combining KPV (α-MSH C-terminal tripeptide), GHK-Cu (copper-binding tripeptide), BPC-157 (body protection compound pentadecapeptide), and TB-500 (Thymosin β4 fragment) into a single 80 mg lyophilized vial. Each component is a well-characterized research peptide with its own substantial preclinical research literature in repair-related research models. The combination provides a standardized multi-component research-context tool for combination-pharmacology research applications addressing multiple complementary repair-research mechanisms simultaneously.

The four components engage different proposed mechanisms: KPV provides anti-inflammatory effects (NF-κB and cytokine modulation), GHK-Cu provides extracellular-matrix and broad gene-expression effects (copper-dependent enzymology and collagen synthesis), BPC-157 provides multi-axis tissue-repair signaling (vascular, growth-factor, mucosal-protective), and TB-500 provides actin-dynamics and cellular-migration effects. Combination research is appropriate where multi-mechanism combination is the experimental variable; single-component research is appropriate for mechanism-attribution work.

The preparation is supplied as a lyophilized powder reconstituted with bacteriostatic water and is provided for laboratory and research-supply use. It is not an approved medicine, not a dietary supplement, and not intended for human consumption. The educational content on this page provides scientific and historical context for the research-supply combination format.